NEA 17 fund linked to Korro Bio (KRRO) 10% owner adds shares, warrants

Rhea-AI Filing Summary

Florence Anthony A. Jr. reported open-market purchase transactions in this Form 4 filing.

Korro Bio, Inc. disclosed that investment fund New Enterprise Associates 17, L.P. (NEA 17), an entity associated with 10% owner Anthony A. Florence Jr., entered into a Subscription Agreement with the company. On March 10, 2026, NEA 17 acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.11 per share. Following the transaction, NEA 17 held 242,945 pre-funded warrants (each exercisable into one share of Common Stock at $0.001 per share) and 1,297,893 shares of Common Stock. The pre-funded warrants are exercisable at any time but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days' notice, not to exceed 19.99%. Florence is a manager of the NEA 17 general partner and disclaims beneficial ownership of portions of these securities in which he has no pecuniary interest.

Insights

Equity ownership and governance analyst

A 10% owner–affiliated fund increased its Korro Bio exposure via a direct purchase from the company.

The filing shows NEA 17, a fund associated with 10% owner Anthony A. Florence Jr., acquiring 242,945 Pre-Funded Warrants and 207,100 Common Shares under a Subscription Agreement dated March 9, 2026. This is a primary issuance by Korro Bio, not a secondary trade.

Pre-funded warrants behave economically like equity because they have a nominal $0.001 exercise price and are exercisable at any time, but they are constrained by a 9.99% ownership cap, adjustable up to 19.99% with 61 days' notice. That limiter affects how quickly the fund can convert its warrant position into common stock.

Florence is a manager of the NEA 17 general partner and is a 10% owner, yet he disclaims beneficial ownership of portions of the position where he lacks pecuniary interest. From a governance perspective, investors may focus on NEA 17’s enlarged stake and the ownership caps that shape its future ability to exercise the warrants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Florence Anthony A. Jr.

(Last) (First) (Middle)

104 5TH AVE

19TH FLOOR

(Street)

NEW YORK NY 10011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P(1)		207,100	A	$11.11	1,297,893	I	See Note 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		P(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	I	See Note 2(2)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Korro Bio (KRRO) disclose in this Form 4 filing?

Korro Bio reported a purchase of securities by NEA 17, a fund linked to 10% owner Anthony A. Florence Jr. NEA 17 acquired common stock and pre-funded warrants directly from the company under a Subscription Agreement dated March 9, 2026.

How many Korro Bio shares and warrants did NEA 17 acquire?

NEA 17 acquired 207,100 shares of Common Stock and 242,945 Pre-Funded Warrants. The stock was purchased at $11.11 per share, while the warrants relate to underlying shares priced at $11.109 per share with a $0.001 exercise price.

What are the key terms of Korro Bio’s pre-funded warrants held by NEA 17?

The pre-funded warrants are exercisable at any time with a nominal $0.001 exercise price. A beneficial ownership cap limits exercises above 9.99% of outstanding common stock, adjustable by the holder with 61 days’ notice up to 19.99%.

What is Anthony A. Florence Jr.’s relationship to the NEA 17 holdings in Korro Bio?

Florence is a manager of NEA 17’s general partner and a 10% owner of Korro Bio. The securities are directly owned by NEA 17, and Florence disclaims beneficial ownership of portions where he has no pecuniary interest under Section 16 definitions.

How large is NEA 17’s Korro Bio position after this transaction?

After the purchases, NEA 17 holds 1,297,893 shares of Korro Bio Common Stock and 242,945 pre-funded warrants. Each warrant is exercisable into one share, subject to the stated ownership limits that restrict how much can be exercised at any time.